Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients

References

• Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. European Association of Urology. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2013;64:639–53.
   Google Scholar
• Lamm DL. Advances in the treatment of superficial bladder cancer: optimizing BCG immunotherapy. Introduction. Eur Urol 1995;27(Suppl 1):1.
   PubMedGoogle Scholar
• Lamm DL. Comparison of BCG with other intravesical agents. Urology 1991;37(Suppl 5):30–2.
   PubMedGoogle Scholar
• Lamm DL. Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000;31(Suppl 3):86–90.
   Google Scholar
• Chopin DK, Gattegno B. Descriptive epidemiology of superficial bladder tumors. Prog Urol 2001;11:955–60.
   PubMedGoogle Scholar
• Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al. EAU guidelines on non-muscle- invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997–1008.
   PubMed Web of Science ®Google Scholar
• Pfister C, Roupret M, Wallerand H, Davin JL, Quintens H, Guy L, et al. Recommandations en onco-urologie 2010: tumeurs urothéliales. Prog Urol 2010;20:255–74.
   PubMedGoogle Scholar
• Prescott S, Jackson AM, Hawkyard SJ, Alexandroff AB, James K. Mechanisms of action of intravesical bacille Calmette-Guerin: local immune mechanisms. Clin Infect Dis 2000;31(Suppl 3):91–3.
   Google Scholar
• Wittes RC. Immunology of bacille Calmette-Guerin and related topics. Clin Infect Dis 2000;31(Suppl 3):S59–63.
   PubMedGoogle Scholar
• Debois H, Loupi E, Saliou P. Suivi de la tolérance de la BCG thérapie endovésicale en France: analyse quantitative des évènements indésirables graves notifiés sur cinq ans. Prog Urol 2001;12:604–8.
   Google Scholar
• Lamm DL. Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 1992;19:565–72.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Palou J, Soloway M, Lamm D, Brausi M, Spermon JR, et al. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Eur Urol Suppl 2008;7:667–74.
   Web of Science ®Google Scholar
• Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 2014;65:69–76.
   PubMed Web of Science ®Google Scholar
• Le Cam Y, Beuscart C, Le Moal S, Bousser J, Zimbacca F. Septicémie à BCG: une complication grave de la BCG-thérapie intravésicale. Med Mal Infect 1999;29:483–6.
   Google Scholar
• Fradet V, Gaudreau C, Perrotte P, Côté J, Paquin J-M. Management of hepatic granulomatous tuberculosis complicating intravesical BCG for superficial bladder cancer. Can Urol Assoc J 2007;1:269.
   PubMed Web of Science ®Google Scholar
• Álvarez-Múgica M, Gómez JMF, Vázquez VB, Monzón AJ, Rodríguez JMF, Robles LR. Pancreatic and psoas abscesses as a late complication of intravesical administration of bacillus Calmette-Guerin for bladder cancer: a case report and review of the literature J Med Case Rep 2009;3:7323.
   Google Scholar
• Hellinger WC, Oldenburg WA, Alvarez S. Vascular and other serious infections with Mycobacterium bovis after bacillus of Calmette-Guerin therapy for bladder cancer. South Med J 1995;88:1212–16.
   PubMedGoogle Scholar
• Viallard JF, Denis D, Texier-Maugein J, Parrens M, Faure I, Pellegrin JL, et al. Disseminated infection after bacille Calmette-Guerin instillation for treatment of bladder carcinoma. Clin Infect Dis 1999;29:451–2.
   PubMedGoogle Scholar
• Gonzalez OY, Musher DM, Brar I, Furgeson S, Boktour MR, Septimus EJ, et al. Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 2003;36:140–8.
   PubMed Web of Science ®Google Scholar
• Sfaxi M, Langar H, Ouni A, Riahi Y, El Aidli S, Daghfous R, et al. Systemic BCG reactions after intravesical BCG therapy. A report of four cases. Therapie 2008;63:43–7.
   Google Scholar
• Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 29-1998. A 57-year-old man with fever and jaundice after intravesical instillation of bacille Calmette-Guérin for bladder cancer. N Engl J Med 1998;339:831–7.
   PubMedGoogle Scholar
• Elkabani M, Greene JN, Vincent AL, VanHook S, Sandin RL. Disseminated Mycobacterium bovis after intravesicular bacillus Calmette-Guerin treatments for bladder cancer. Cancer Control 2000;7:476–81.
   PubMedGoogle Scholar
• Mcparland C, Cotton DJ, Gowda KS, Hoeppner VH, Martin WT, Weckworth PF. Miliary Mycobacterium bovis induced by intravesical bacille Calmette-Guérin immunotherapy. Am Rev Respir Dis 1992;146:1330–3.
   PubMedGoogle Scholar
• Tuncer S, Tekin MI, Ozen H, Bilen C, Unal S, Remzi D. Detection of bacillus Calmette-Guerin in the blood by the polymerase chain reaction method of treated bladder cancer patients. J Urol 1997;158:2109–12.
   PubMedGoogle Scholar
• Durek C, Jurczok A, Werner H, Jocham D, Böhle A. Optimal treatment of systemic Bacillus Calmette-Guerin infection: investigations in an animal model. J Urol 2002;168: 826–31.
   PubMed Web of Science ®Google Scholar
• Koukol SC, DeHaven JI, Riggs DR, Lamm DL. Drug therapy of bacillus Calmette-Guérin sepsis. Urol Res 1995; 22:373–6.
   PubMedGoogle Scholar
• Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007;12:20–37.
   PubMed Web of Science ®Google Scholar
• Strock V, Dotevall L, Sandberg T, Gustafsson CK, Holmang S. Late bacilli. Calmette-Guerin infection with a large focal urinary bladder ulceration as a complication of bladder cancer treatment. BJU Int 2011;107:1592–7.
   Google Scholar
• Saint F. Prévention et traitement des effets indésirables associés aux instillations endo-vésicales de BCG. Prog Urol 2006;16:780–5.
   Google Scholar
• Saint F, Salomon L, Quintela A, Cicco A, Abbou CC, Chopin DK. Classification, favorising factors, prevention and treatment of side effects associated to bacillus Calmette-Guerin in treatment of superficial bladder tumors. Ann Urol 2002;36:120–31.
   PubMedGoogle Scholar
• Lamm DL, Van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147: 596–600.
   PubMed Web of Science ®Google Scholar
• Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK. BCG intravesical instillations: recommendations for side-effects management. Eur Urol 2000;37(Suppl 1):33–6.
   PubMedGoogle Scholar
• DeHaven JI, Traynellis C, Riggs DR, Ting E, Lamm DL. Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guerin toxicity. J Urol 1992;147:738–42.
   PubMed Web of Science ®Google Scholar